Noorani, Imran http://orcid.org/0000-0003-4289-2345
Mischel, Paul S. http://orcid.org/0000-0002-4560-2211
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Article History
Accepted: 10 August 2022
First Online: 21 September 2022
Competing interests
: P.S.M. is a co-founder of Boundless Bio, a company focused on developing new treatments for patients with ecDNA-driven cancers; he has equity in the company and chairs the scientific advisory board, for which he is compensated. C.S. has received grant funding from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Invitae (previously ArcherDx), Ono Pharmaceutical, Pfizer and Roche/Ventana Medical Systems. C.S. is an advisory board member for AstraZeneca and Chief Investigator of the AstraZeneca MERMAID-1 and MERMAID-2 clinical trials, and is also Chief Investigator of the NHS-Galleri trial sponsored by GRAIL. C.S. has consulted for Achilles Therapeutics, Amgen, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Genentech, GRAIL, GSK, Illumina, Medicxi, Metabomed, MSD, Novartis, Pfizer, Roche Innovation Centre Shanghai, Roche/Ventana Medical Systems, and the Sarah Cannon Research Institute. C.S. held stock options in Apogen Biotechnologies and GRAIL until June 2021, currently has stock options in Bicycle Therapeutics and Epic Bioscience, and has stock options and is a co-founder of Achilles Therapeutics. I.N. declares no competing interests.